Ken Griffin Regenxbio Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Regenxbio Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 16,700 shares of RGNX stock, worth $192,217. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,700
Previous 291,866
94.28%
Holding current value
$192,217
Previous $2.4 Million
93.28%
% of portfolio
0.0%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding RGNX
# of Institutions
189Shares Held
44.3MCall Options Held
138KPut Options Held
117K-
Black Rock Inc. New York, NY8.61MShares$99.1 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.69MShares$54 Million4.99% of portfolio
-
Jpmorgan Chase & CO New York, NY4.04MShares$46.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.34MShares$38.4 Million0.0% of portfolio
-
State Street Corp Boston, MA1.98MShares$22.8 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $498M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...